Pierre‐François Laterre

22.6k total citations · 3 hit papers
182 papers, 12.8k citations indexed

About

Pierre‐François Laterre is a scholar working on Epidemiology, Surgery and Critical Care and Intensive Care Medicine. According to data from OpenAlex, Pierre‐François Laterre has authored 182 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Epidemiology, 47 papers in Surgery and 46 papers in Critical Care and Intensive Care Medicine. Recurrent topics in Pierre‐François Laterre's work include Sepsis Diagnosis and Treatment (61 papers), Intensive Care Unit Cognitive Disorders (23 papers) and Respiratory Support and Mechanisms (21 papers). Pierre‐François Laterre is often cited by papers focused on Sepsis Diagnosis and Treatment (61 papers), Intensive Care Unit Cognitive Disorders (23 papers) and Respiratory Support and Mechanisms (21 papers). Pierre‐François Laterre collaborates with scholars based in Belgium, France and United States. Pierre‐François Laterre's co-authors include Jean‐Louis Vincent, Jean-François Dhainaut, E. Wesley Ely, Jeffrey D. Helterbrand, Charles J. Fisher, Xavier Wittebole, Thierry Dugernier, Howard Levy, Jean Roeseler and Konrad Reinhart and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Pierre‐François Laterre

180 papers receiving 12.3k citations

Hit Papers

Efficacy and Safety of Recombinant Human Activated Protei... 2001 2026 2009 2017 2001 2008 2005 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
    2001 4.0k citations Jean‐Louis Vincent, Pierre‐François Laterre et al. profile →
  2. Hydrocortisone Therapy for Patients with Septic Shock
    2008 1.3k citations Pierre‐François Laterre, Konrad Reinhart et al. profile →
  3. Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
    2005 567 citations Edward Abraham, Pierre‐François Laterre et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pierre‐François Laterre Belgium 50 6.4k 2.8k 2.7k 2.4k 1.5k 182 12.8k
Jean-François Dhainaut France 38 5.6k 0.9× 2.0k 0.7× 2.4k 0.9× 1.8k 0.7× 1.5k 1.0× 77 10.8k
Charles J. Fisher United States 32 6.7k 1.1× 2.4k 0.9× 2.6k 1.0× 1.9k 0.8× 3.3k 2.2× 74 13.1k
Herwig Gerlach Germany 40 7.4k 1.2× 3.2k 1.1× 3.5k 1.3× 2.9k 1.2× 1.4k 0.9× 139 14.2k
Joseph A. Carcillo United States 63 9.5k 1.5× 3.6k 1.3× 3.7k 1.4× 3.0k 1.2× 3.1k 2.1× 291 20.8k
Charles Natanson United States 47 4.4k 0.7× 1.4k 0.5× 1.8k 0.7× 1.4k 0.6× 2.2k 1.4× 173 10.0k
Roland M.H. Schein United States 28 8.9k 1.4× 2.6k 0.9× 3.9k 1.4× 3.1k 1.3× 2.6k 1.7× 55 16.4k
Frank M. Brunkhorst Germany 51 5.7k 0.9× 1.4k 0.5× 2.8k 1.1× 1.7k 0.7× 1.2k 0.8× 183 10.1k
R.A. Balk United States 44 10.5k 1.6× 4.3k 1.5× 4.7k 1.7× 3.3k 1.4× 3.3k 2.2× 242 19.5k
Konrad Reinhart Germany 69 10.2k 1.6× 3.0k 1.1× 5.4k 2.0× 4.7k 2.0× 2.4k 1.6× 283 20.5k
Claudio M. Martin Canada 50 3.1k 0.5× 1.8k 0.7× 3.7k 1.4× 1.9k 0.8× 551 0.4× 168 11.2k

Countries citing papers authored by Pierre‐François Laterre

Since Specialization
Citations

This map shows the geographic impact of Pierre‐François Laterre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre‐François Laterre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre‐François Laterre more than expected).

Fields of papers citing papers by Pierre‐François Laterre

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre‐François Laterre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre‐François Laterre. The network helps show where Pierre‐François Laterre may publish in the future.

Co-authorship network of co-authors of Pierre‐François Laterre

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre‐François Laterre. A scholar is included among the top collaborators of Pierre‐François Laterre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre‐François Laterre. Pierre‐François Laterre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Butler, Joe M., Hessel Peters‐Sengers, Tom D. Y. Reijnders, et al.. (2025). Pathogen-specific host response in critically ill patients with blood stream infections: a nested case–control study. EBioMedicine. 117. 105799–105799. 1 indexed citations
2.
Verroken, Alexia, Julien Favresse, Ahalieyah Anantharajah, et al.. (2024). Optimized Antibiotic Management of Critically Ill Patients with Severe Pneumonia Following Multiplex Polymerase Chain Reaction Testing: A Prospective Clinical Exploratory Trial. Antibiotics. 13(1). 67–67. 4 indexed citations
3.
Liu, Xin, Suzanne L. Parker, Alexia Verroken, et al.. (2023). Population pharmacokinetics and dosing simulations of total and unbound temocillin in the plasma and CSF of neurocritically ill patients with external ventricular drain-related cerebral ventriculitis. Journal of Antimicrobial Chemotherapy. 79(2). 429–442. 1 indexed citations
4.
Morimont, Laure, Mélanie Dechamps, Clara David, et al.. (2022). NETosis and Nucleosome Biomarkers in Septic Shock and Critical COVID-19 Patients: An Observational Study. Biomolecules. 12(8). 1038–1038. 24 indexed citations
5.
Gérard, Ludovic, Marylène Lecocq, Caroline Bouzin, et al.. (2021). Increased Angiotensin-Converting Enzyme 2 and Loss of Alveolar Type II Cells in COVID-19–related Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine. 204(9). 1024–1034. 48 indexed citations
6.
7.
Dugernier, Jonathan, Michel Hesse, Émilie Bialais, et al.. (2017). Aerosol Delivery with Two Nebulizers Through High-Flow Nasal Cannula: A Randomized Cross-Over Single-Photon Emission Computed Tomography-Computed Tomography Study. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 30(5). 349–358. 48 indexed citations
8.
Montravers, Philippe, Hervé Dupont, Marc Léone, et al.. (2015). Prise en charge des infections intra-abdominales. Anesthésie & Réanimation. 1(1). 75–99. 11 indexed citations
9.
Achouiti, Ahmed, Dirk Föll, Thomas Vogl, et al.. (2013). S100A12 and Soluble Receptor for Advanced Glycation End Products Levels During Human Severe Sepsis. Shock. 40(3). 188–194. 28 indexed citations
10.
Zoelen, Marieke A. D. van, Thomas Vogl, Dirk Foell, et al.. (2009). Expression and Role of Myeloid-related Protein-14 in Clinical and Experimental Sepsis. American Journal of Respiratory and Critical Care Medicine. 180(11). 1098–1106. 112 indexed citations
11.
Laterre, Pierre‐François, Gary Garber, Howard Levy, et al.. (2005). Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study*. Critical Care Medicine. 33(5). 952–961. 132 indexed citations
12.
Angus, Derek C., Pierre‐François Laterre, E. Wesley Ely, et al.. (2004). The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis *. Critical Care Medicine. 32(11). 2199–2206. 99 indexed citations
13.
Opal, Steven M., Pierre‐François Laterre, Edward Abraham, et al.. (2004). Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial*. Critical Care Medicine. 32(2). 332–341. 103 indexed citations
14.
Macias, William L., B. Vallet, Gordon R. Bernard, et al.. (2004). Sources of variability on the estimate of treatment effect in the PROWESS trial: Implications for the design and conduct of future studies in severe sepsis*. Critical Care Medicine. 32(12). 2385–2391. 38 indexed citations
15.
Ely, E. Wesley, Pierre‐François Laterre, Derek C. Angus, et al.. (2003). Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Critical Care Medicine. 31(1). 12–19. 192 indexed citations
16.
Dhainaut, Jean François, et al.. (2002). Drotrecogin alfa (activated) in severe sepsis patients with 2 or more organ dysfunctions. Intensive Care Medicine. 28. 4 indexed citations
17.
18.
Wittebole, Xavier & Pierre‐François Laterre. (2001). Prise en charge des hépatites fulminantes d'origine toxique en réanimation. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)). 10(4). 418–425. 1 indexed citations
19.
Frans, A., T Clerbaux, B. Detry, et al.. (1998). Effect of inorganic ions on the oxyhemoglobin dissociation curve of severely ill patients.. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)). 46(1). 8–14. 3 indexed citations
20.
Lerut, Jan, Michel Mourad, Pierre Goffette, et al.. (1994). Transjugular Portosystemic Stent Shunting in Liver Transplanted Patients. Hepatology. 20(4). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean-François Dhainaut Breakdown of academic impact, for papers by Charles J. Fisher Breakdown of academic impact, for papers by Herwig Gerlach Breakdown of academic impact, for papers by Joseph A. Carcillo Breakdown of academic impact, for papers by Charles Natanson Breakdown of academic impact, for papers by Roland M.H. Schein Breakdown of academic impact, for papers by Frank M. Brunkhorst Breakdown of academic impact, for papers by R.A. Balk Breakdown of academic impact, for papers by Konrad Reinhart Breakdown of academic impact, for papers by Claudio M. Martin
Rankless by CCL
2026